**Supplementary Figure S1.** Forest plot comparing lenvatinib and HAIC group which representing hazard ratio, p-value, and median OS in each subgroup

****

**Supplementary Figure S2.** Forest plot comparing lenvatinib and HAIC group which representing hazard ratio, p-value, and median PFS in each subgroup



**Supplementary Figure S3.** Kaplan-Meier curve representing survival difference between patients with salvage therapy and without salvage therapy at the end of HAIC or lenvatinib treatment, in PSM cohort.



**Supplementary Table S1. Salvage therapy following lenvatinib or HAIC**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Lenvatinib (n = 46) | HAIC (n = 47) | *P* |
| Salvage therapy | 14 (30.4) | 26 (55.3) | 0.015 |
| Sorafenib | 1 | 11 |  |
| Lenvatinib | - | 5 |  |
| Nivolumab | 4 | 1 |  |
| Regorafenib | 2 | 0 |  |
| Ramucirumab | 0 | 1 |  |
| Atezolizumab-Bevacizumab | 0 | 1 |  |
| TACE | 3 | 6 |  |
| HAIC | 1 | - |  |
| TARE | 0 | 1 |  |
| Systemic cytotoxic chemotherapy | 3 | 0 |  |

Data are given as n (%). HAIC, hepatic arterial infusion chemotherapy; TACE, transarterial chemoembolization; TARE, transarterial radioembolization.